Retinitis pigmentosa Trials in London, United Kingdom
Conditions / Retinitis pigmentosa / London, United Kingdom
Retinitis pigmentosa is a medical condition with active clinical research programs worldwide.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03349242 | Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR) | COMPLETED | — |
| NCT05589714 | Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants | RECRUITING | — |
| NCT05176717 | Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) | TERMINATED | PHASE2/PHASE3 |
| NCT04765345 | Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F | ACTIVE_NOT_RECRUITING | — |
| NCT01847365 | TES for the Treatment of RP | COMPLETED | NA |
| NCT00407602 | Argus® II Retinal Stimulation System Feasibility Protocol | COMPLETED | NA |
| NCT01024803 | Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients | COMPLETED | NA |
| NCT02670980 | Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy | COMPLETED | NA |
| NCT05158296 | Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) | TERMINATED | PHASE2/PHASE3 |
| NCT05537220 | Oral N-acetylcysteine for Retinitis Pigmentosa | ACTIVE_NOT_RECRUITING | PHASE3 |